Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$3.4MCash on Hand
3.3mo Cash Runway
Follow AEON by emailGet an email when AEON reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about AEON, unsubscribe in one click. Privacy
📣 What AEON Says Is Next
second quarter of 2027 · ABP-450: “The Company expects its cash and cash equivalents as of September 30, 2026, together with these warrant proceeds, to fund operations into the second quarter of 2027, supporting continued execution of the comparative analytical program, preparations for and planned initiation of the CMAP pharmacodynamic study, and ongoing regulatory activities. Exhibit 99.1 PRESS RELEASE Planned ABP-450 Development Milestones”
Company press release, Nov 16, 2026 · SEC filing
first half of 2027 · “The Company plans to initiate a multi-lot forced degradation comparability study in the first half of 2027. o Forced degradation testing is widely used in analytical comparability assessments for complex biologics and complements characterization performed on unstressed material.”
Company press release, Nov 16, 2026 · SEC filing
fourth quarter of 2026 · “AEON intends to incorporate the FDA’s feedback and advance the study under an investigational new drug application (“IND”), which the Company expects to submit in the fourth quarter of 2026.”
Company press release, Sep 30, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 16, 2026 ·
Regulatory Reported Q3 2026 results and a corporate update: FDA Type 2b feedback on the ABP-450 biosimilar strategy, a CMAP pharmacodynamic study IND submitted with initiation planned for Q1 2027, and about $6.2 million in milestone warrant proceeds. Added former FDA neurology official Paul Lee as acting Chief Regulatory Officer. Form 8-K · SEC filing · Press release
Nov 3, 2026 ·
Financing AEON amended its two-year milestone warrants, cutting the exercise price from $0.3221 to $0.20 per share, effective November 2, 2026. Holders agreed to exercise, with the company expecting about $6.2 million in gross proceeds. The warrants expire November 16, 2026. Form 8-K · SEC filing
Nov 3, 2026 ·
Financing Warrant holders amended the Two-Year Warrants, cutting their exercise price from $0.3221 to $0.20 per share and from $0.3220 to $0.1999 per pre-funded warrant. Holders are expected to exercise, yielding about $6.2 million in gross proceeds. The warrants expire November 16, 2026. Form 424B3 · SEC filing
Oct 26, 2026 ·
Shareholder vote AEON Biopharma asks stockholders to vote at a December 15, 2026 special meeting on four proposals: authority for one reverse stock split at a 1-for-2 to 1-for-100 ratio, and amendments adding pre-funded warrant shares to the equity plan and ESPP evergreen calculations. An adjournment proposal is also included. Form DEF 14A · SEC filing
Oct 23, 2026 ·
Furnished an October 2026 corporate presentation (Exhibit 99.1) on its investor relations website, outlining plans for ABP-450 as a potential BOTOX substitute. The presentation covers an IND for a planned CMAP pharmacodynamic study and the FDA 351(k) pathway. Form 8-K · SEC filing · Press release
Sep 30, 2026 ·
Regulatory FDA agreed in principle to AEON's two-stage CMAP pharmacodynamic study design for ABP-450, a proposed BOTOX biosimilar, and said prior Daewoong comparative studies may be submitted as supportive evidence. AEON will not start a standalone efficacy study now and plans to return to FDA in 2027. Form 8-K · SEC filing · Press release
Aug 12, 2026 ·
Earnings Reported Q2 2026 results: cash of $3.4 million as of June 30, 2026, excluding about $13.6 million net proceeds from a July 2026 public offering with up to $34.0 million more from milestone warrants. Cash expected to last into Q1 2027. FDA feedback on the next development phase is expected in H2 2026. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Jun 2024 · Phase 2 · Results Expected · Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults Registry primary completion date, not a results date
Jul 2023 · Phase 2 · Results Expected · Extension Study of ABP-19000 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 in Cervical Dystonia Registry primary completion date, not a results date
Jul 2022 · Phase 2 · Results Expected · A Phase 2 Study to Evaluate the Safety and Efficacy of ABP-450 in the Treatment of Cervical Dystonia Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
AEON holds $3.4M in cash and short-term investments (as of Jun 30, 2026) and burns about $3.2M/quarter from operations,
an estimated runway of 3.3 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:80 · High
Cash runway 3 months +40
ATM program on file since Jun 2025 +15
Shelf registration (S-3, Feb 2026) +10
Going-concern doubt in the latest 10-Q +15As a result of these conditions, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern and to meet its obligations as they become due within one year after the date that these condensed consolidated financial statements are issued.10-Q, Nov 2026
Share count 84,121,648 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full AEON picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AEON and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.